David Meeker, Rhythm Pharmaceuticals CEO

Rhythm Phar­ma knocked off stride as mixed PhI­II obe­si­ty da­ta for its sole big drug look ‘meh’ to many

Just a few weeks af­ter Rhythm Phar­ma­ceu­ti­cals $RYTM snagged an FDA OK for set­melan­otide in 3 rare ge­net­ic dis­or­ders that trig­ger obe­si­ty, the biotech is strug­gling to make a good case for a cru­cial mar­ket ex­pan­sion.

Rhythm CEO David Meek­er spot­light­ed the pos­i­tive da­ta at hand for Bardet-Biedl syn­drome and Al­ström syn­drome, two oth­er ail­ments that trig­ger an in­sa­tiable hunger. But their 3 pa­tients with Al­ström syn­drome all failed the pri­ma­ry end­point in the study while the BBS ef­fi­ca­cy rate dwin­dled sig­nif­i­cant­ly from its Phase II re­sults, drag­ging down the over­all re­sults that left in­vestors and an­a­lysts won­der­ing just how big this suc­cess re­al­ly was.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.